[{"indications": "Indications\u00a0adjuvant treatment of oestrogen-receptor-positive early breast cancer\r\nin postmenopausal women; advanced breast cancer in postmenopausal\r\nwomen (including those in whom other anti-oestrogen therapy has failed);\r\nearly invasive breast cancer in postmenopausal women after standard\r\nadjuvant tamoxifen therapy; pre-operative treatment in postmenopausal\r\nwomen with localised hormone-receptor-positive breast cancer to allow\r\nsubsequent breast conserving surgery", "name": "LETROZOLE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.4 Hormone antagonists", "8.3.4.1 Breast cancer"], "cautions": "Cautions\u00a0susceptibility to osteoporosis (assess\r\nbone mineral density before treatment and at regular intervals)", "side-effects": "Side-effects\u00a0hot flushes, nausea, vomiting, fatigue, dizziness,\r\nheadache, dyspepsia, constipation, diarrhoea, depression, anorexia,\r\nappetite increase, hypercholesterolaemia, alopecia, increased sweating,\r\nrash, peripheral oedema, musculoskeletal pain, osteoporosis, bone\r\nfracture; less commonly hypertension, palpitation,\r\ntachycardia, dyspnoea, cough, drowsiness, insomnia, anxiety, memory\r\nimpairment, dysaesthesia, taste disturbance, pruritus, dry skin, urticaria,\r\nthrombophlebitis, abdominal pain, urinary frequency, urinary-tract\r\ninfection, vaginal bleeding, vaginal discharge, breast pain, pyrexia,\r\nmucosal dryness, stomatitis, cataract, eye irritation, blurred vision,\r\ntumour pain, arthritis, leucopenia, general oedema; rarely pulmonary embolism, arterial thrombosis, cerebrovascular infarction", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/56613.htm", "doses": ["2.5\u00a0mg daily"], "pregnancy": "Pregnancy\u00a0avoid (toxicity in animal studies);\r\nmanufacturer advises effective contraception required until postmenopausal\r\nstatus fully established "}]